Africa Leads New HIV Treatment Study for 40M Worldwide

Researchers across four African nations are leading a breakthrough study that could save countless lives among the 40.8 million people living with HIV worldwide.

The Ndovu Study is tackling one of HIV treatment's biggest challenges: what happens when the primary drug used globally stops working. When people struggle to take their medication consistently, the virus can develop resistance to dolutegravir, the cornerstone drug in most HIV treatment plans today.

Scientists in Kenya, Tanzania, Lesotho, and Mozambique are enrolling patients whose treatment has stopped working effectively. They're providing intensive support to help people stick to their medication schedules while testing for drug resistance and catching dangerous complications early.

The stakes are high. When HIV treatment fails, patients face plummeting immune system counts and life-threatening infections like tuberculosis and cryptococcal meningitis. With limited backup treatment options available, understanding how to manage dolutegravir resistance is urgent.

Dr. Loice Ombajo, the study's chief investigator and infectious disease specialist at the University of Nairobi, emphasizes the critical need. "We urgently need evidence to guide how patients should be managed when they fail treatment and when drug resistance develops," she said.

The study represents a powerful example of African-led research solving global health challenges. Teams are working directly with their national health ministries to ensure findings immediately shape treatment policies and patient care.

The Ripple Effect

This research extends far beyond Africa's borders. As countries worldwide rely on dolutegravir-based treatments, the evidence emerging from Ndovu will inform international guidelines on managing treatment failure everywhere.

The collaboration brings together the Centre for Epidemiological Modelling and Analysis at the University of Nairobi, Muhimbili University in Tanzania, Solidar Med in Lesotho, and Mozambique's National Institute of Health. The Bill & Melinda Gates Foundation is funding the work.

Dr. Patricia Munseri, leading the Tanzania arm of the study, expressed confidence in generating high-quality data that meets rigorous international standards. She sees it as an opportunity to strengthen collaboration across the African continent.

In January 2026, the team gathered in Naivasha, Kenya, to review their progress and align priorities for the next phase. Early findings show promise, with researchers committed to rapidly translating evidence into action that saves lives.

Despite major advances in HIV treatment over recent decades, 630,000 people still died from HIV-related illnesses in 2024. The Ndovu Study addresses this reality head-on by strengthening health systems and ensuring no patient is left behind when first-line treatments fail.

African researchers are proving that solutions to global health crises can emerge from the communities most affected, reshaping the future of HIV care for millions.